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Germline Mutation in EXPH5 Implicates
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The Rab GTPase Rab27B and one of its effector proteins, Slac2-b (also known as EXPH5, exophilin-5), have putative roles in intracellular
vesicle trafficking but their relevance to human disease is not known. By using whole-exome sequencing, we identified a homozygous
frameshift mutation in EXPH5 in three siblings with inherited skin fragility born to consanguineous Iraqi parents. All three individuals
harbor themutation c.5786delC (p.Pro1929Leufs*8) in EXPH5, which truncates the 1,989 amino acid Slac2-b protein by 52 residues. The
clinical features comprised generalized scale-crusts and occasional blisters, mostly induced by trauma, as well as mild diffuse pigmentary
mottling on the trunk and proximal limbs. There was no increased bleeding tendency, no neurologic abnormalities, and no increased
incidence of infection. Analysis of an affected person’s skin showed loss of Slac2-b immunostaining (C-terminal antibody), disruption of
keratinocyte adhesion within the lower epidermis, and an increased number of perinuclear vesicles. A role for Slac2-b in keratinocyte
biology was supported by findings of cytoskeletal disruption (mainly keratin intermediate filaments) and decreased keratinocyte adhe-
sion in both keratinocytes from an affected subject and after shRNA knockdown of Slac2-b in normal keratinocytes. Slac2-b was also
shown to colocalize with Rab27B and b4 integrin to early adhesion initiation sites in spreading normal keratinocytes. Collectively,
our findings identify an unexpected role for Slac2-b in inherited skin fragility and expand the clinical spectrum of human disorders
of GTPase effector proteins.Collectively termed epidermolysis bullosa, the inherited
skin fragility disorders reflect a clinically and genetically
heterogeneous group of conditions that result from muta-
tions in at least 14 genes that mostly encode structural
proteins involved in keratinocyte cell-cell or cell-matrix
adhesion.1 Despite considerable progress in the molecular
characterization of the different forms of epidermolysis
bullosa, some variants thereof remain unclassified. Never-
theless, recent technical innovations in next-generation
sequencing now provide new opportunities to identify
gene mutations in unresolved cases. In this report, we
used whole-exome sequencing to identify an additional
cause of inherited skin fragility, namely mutations in
EXPH5 (MIM 612878) encoding the Rab27B GTPase
effector protein Slac2-b (also known as exophilin-5).
We investigated an Iraqi family in which three of eight
siblings born to first-cousin parents had inherited skin
fragility (Figure 1A). The clinical features were noted
from early childhood and mainly comprised trauma-
induced scale crusts and intermittent skin blistering that
was mostly induced by trauma (e.g., direct injury or adhe-
sive tape), although some appeared spontaneously (Figures
1B and 1C; Figure S1 available online). Some of the crusted
areas were hemorrhagic and accompanied by occasional
bruising. Most lesions cleared over several weeks to leave
slightly atrophic scars and moderate postinflammatory
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The American Jouand hypopigmentation was noted on the trunk and prox-
imal limbs. There was no increased bleeding tendency
(normal platelet counts and coagulation studies demon-
strated in individual II-2), no neurologic abnormalities,
and no increased incidence of infection. Hair color was
normal. No clinical abnormalities were noted in either
parent or reported in any other relative.
To investigate the etiology of the blistering, we first
assessed by immunohistochemistry and transmission
electron microscopy a nonlesional skin biopsy taken
from the upper arm of individual II-2 under local anes-
thetic. The subject’s legal guardian provided written and
informed consent according to a protocol approved by
the St. Thomas’ Hospital Ethics Committee (Molecular
basis of inherited skin disease: 07/H0802/104). Blood and
skin samples (ellipse of skin taken under local anesthesia
by 1% lignocaine) were obtained in adherence to the
Helsinki guidelines. Light microscopy showed mild
acanthosis and hyperkeratosis and an irregular ruffled or
jagged appearance at the dermal-epidermal junction
(Figure 1D). Immunolabeling showed normal intensity
basement membrane zone staining with antibodies to
laminin-332, keratin 14, plectin, tetraspanin CD151,
collagen IV, collagen VII, collagen XVII, and b4 integrin,
although some staining patterns differed from normal
control skin (Figure S2). Notably, labeling at the dermal-
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Figure 1. Pedigree and Skin Pathology in This Autosomal-Recessive Skin Fragility Disorder
(A) The family pedigree. Squares denote male family members, and circles female family members; filled-in symbols indicate clinically
affected individuals.
(B) Affected individual II-2 with skin crusting at the site of a recent trauma-induced erosion.
(C) Higher magnification of the crusted erosion. Additional clinical images are shown in Figure S1.
(D) Light microscopy of skin sampled from the upper arm reveals mild acanthosis and hyperkeratosis as well as a ruffled appearance to
the dermal-epidermal junction (Richardson’s stain; scale bar represents 50 mm).
(E) Low-magnification transmission electron micrograph shows widening of spaces between keratinocytes in the lower epidermis with
some aggregation of keratin filaments (scale bar represents 3 mm).
(F) Higher-magnification transmission electron micrograph reveals keratin filament disruption (blue arrow) as well as perinuclear accu-
mulation of vesicles (green arrow) (scale bar represents 0.5 mm).
(G) There is also focal accumulation of vesicles close to the plasma membrane (green arrow) (scale bar represents 0.25 mm).a broader jagged pattern, keratin 14 labeling was more
diffuse pan-epidermal, and CD151 staining was confined
to the dermal-epidermal junction in contrast to the pericel-
lular pattern seen in control basal keratinocytes (Figure S2).
Low-magnification transmission electron microscopy
revealed basement membrane keratinocyte disruption
within the lower epidermis (Figure 1E). Higher magnifica-
tion showed aggregated intermediate filaments as well as
an increased number of perinuclear vesicles (Figure 1F)
and some vesicles clustered near the plasma membrane
(Figure 1G). Collectively, however, the clinicopathologic
features were not diagnostic for any particular subtype of
epidermolysis bullosa.
Next, after obtaining approval from the ethics com-
mittee and informed consent from all subjects, we ex-
tracted genomic DNA from peripheral blood or saliva
samples from ten individuals (all eight siblings and both
parents) in compliance with the Declaration of Helsinki
Principles. We first excluded a possible diagnosis of epider-1116 The American Journal of Human Genetics 91, 1115–1121, Decemolysis bullosa simplex (MIM 131800) by sequencing
KRT5 and KRT14 (MIM 148040, 148066) that encode
keratin 5 and 14, respectively (data not shown). Then, by
using DNA from subject II-2, whole-exome capture was
performed by in-solution hybridizationwith the SureSelect
All Exon 50MbVersion 4.0 (Agilent) followed bymassively
parallel sequencing (Illumina HiSeq2000) with 100 bp
paired-end reads. More than 8.6 gigabases of mappable
sequence data was generated, such that >90% of the
coding bases of the exome defined by the GENCODE
Project were represented by at least 20 reads. Variant
profiles were generated with our in-house variant-calling
pipeline.2 In brief, reads generated on the Illumina
HiSeq2000 platform were aligned to the reference human
genome with the Novoalign software package (Novocraft
Technologies Sdn Bhd). Duplicate reads, resulting from
PCR clonality or optical duplicates, and reads mapping
to multiple locations were excluded from downstream
analysis. Depth and breadth of sequence coverage wasmber 7, 2012
Figure 2. Identification of EXPH5 Mutations in This Pedigree
(A) Sequencing of genomic DNA from individual II-2 reveals a homozygous 1 bp deletion in EXPH5, c.5786delC. Family members II-6
and II-8 were also homozygous for this mutation.
(B) Heterozygosity for this frameshift mutation was also demonstrated in individual I-1 (illustrated), as well as subjects I-2, II-4, and II-5.
(C) Wild-type (WT) sequence is shown for control DNA, which was also demonstrated in family members II-1, II-3, and II-7.
(D) Immunolabeling with a C-terminal antibody to Slac2-b (clone 99021, Abcam, Cambridge UK; working dilution 1:100) shows
a complete absence of staining in an affected person’s skin (scale bar represents 50 mm).
(E) In contrast, in control skin, there is cytoplasmic staining within basal and some suprabasal keratinocytes (scale bar represents 50 mm).
(F) Schematic representation of the known protein binding partners and disease associations for Slac2-a (also known as Slp4-a) and Slac2-
b. Slac2-a contains a N-terminal Slp-homology domain (SHD) that binds to Rab27A, a central myosin-binding domain, and a C-terminal
actin-binding domain. In contrast, the protein-protein interactions for Slac2-b are less well defined: there is a Rab-binding N-terminal
SHD domain (amino acids 7–57) but no other homology-predicted binding sites and, apart from this report, there are no known disease
associations.calculated with custom scripts and the BedTools package.3
Single-nucleotide substitutions and small insertion dele-
tions were identified and quality filtered with the SamTools
software package and in-house software tools.4 Variants
were annotated with respect to genes and transcripts
with the Annovar tool.5 Identified variants were cross-
referenced with publicly available variant data (dbSNP135
and 1000 Genomes Project) and approximately 400
control exome variant profiles generated with the same
methodology in our laboratory. The control exomes are
predominantly of European ancestry but also include
approximately 60 individuals of Middle Eastern origin.
We identified 373 previously unobserved variants (25
homozygous, 348 heterozygous). Of these, given the
consanguinity in the Iraqi pedigree, we noted a homozy-
gous 1 bp deletion in EXPH5 (RefSeq accession number
NM_015065.2, c.5786del in exon 6, p.Pro1929Leufs*8).
EXPH5 encodes the Rab27B GTPase effector protein
Slac2-b (also known as exophilin-5). None of the other
homozygous variants represented clear loss-of-function
mutations and by using Sanger sequencing we confirmedThe American Jouthe presence and segregation of the mutation in the pedi-
gree (Figure 2A). By sequencing, we then excluded this
mutation in 200 control chromosomes (mixed Iraqi,
Iranian, Kuwaiti, and Omani populations). We also
evaluated the significance of the cosegregation of the
c.5786delC variant with the disease status in the pedigree
by using parametric linkage analysis with the Merlin soft-
ware package.6 Analysis was undertaken on the assump-
tion of the parents being first cousins (indicated by the
clinical history) with a fully penetrant autosomal-recessive
model, an estimate of the disease frequency of 0.00001,
and a frequency of 0.001 for the c.5786delC variant. On
this basis, a generated LOD score of 3.157 provides
evidence of linkage and indicates that the observed cose-
gregation is unlikely to have occurred by chance.
The frameshift mutation occurs within the Pro1929
codon and results in a premature termination codon eight
amino acids downstream that is predicted to truncate
the 1,989 amino acid Slac2-b protein by 52 residues. Im-
munolabeling of skin from an affected family member
by a C-terminal Slac2-b antibody (clone ab99021, Abcam;rnal of Human Genetics 91, 1115–1121, December 7, 2012 1117
Figure 3. Keratinocyte Cell Biology Asso-
ciated with EXPH5 Mutations
(A) Confocal images of normal keratino-
cytes (NHK) and keratinocytes from an
affected individual (II-2 Slac2-b) and in
NHK after Slac2-b knockdown (NHK
Slac2-b kd) stained with phalloidin (to
show F-actin; Phalloidin-Alexa488 and
569, Invitrogen) and antibodies to keratin
intermediate filaments (keratin 14, clone
LLOO2, Abcam). Images show similar
changes in cell morphology and aggrega-
tion of the keratin intermediate filament
network in affected person cells and
knockdown cells (scale bars represent
10 mm).
(B) Keratinocyte adhesion assays demon-
strate reduced cell adhesion to the
basement membrane extracellular matrix
protein laminin-332 for patient cells (II-2
Slac2-b).
(C) Loss of adhesion in these assays is
also shown for knockdown cells: two
knockdown clones are shown, shSlac2-
b(1) and (2).
Bars in (B) and (C) are pooled data from
experiments performed in triplicate,
normalized to respective controls and
representative of three experiments. Error
bars are SEM. *p < 0.01, **p < 0.001.
(D) Confocal microscopy images of
normal keratinocytes plated for 45 min
on laminin-332, fixed and stained with
antibodies to b4 integrin (clone 3E1,
Millipore) and Slac2-b (top) and Slac2-b
and Rab27B (clone AB76779, Abcam)
(bottom). Images indicate that Rab27B is
mainly present in a perinuclear distri-
bution, whereas Slac2-b is more localized
to intracellular vesicles and at the
periphery of spreading cells where some
colocalization with Rab27B and b4 is
seen (arrows). This finding suggests that
Slac2-b colocalizes with Rab27B only in
specific subcellular regions, and this is
coincident with early adhesion sites (scale
bar represents 10 mm).epitope amino acids 1,907–1,956) showed a complete
absence of staining compared to normal control skin
(Figures 2D and 2E). The mutation occurs in exon 6 of
EXPH5 close to the 30 end of the gene and therefore
might not be expected to have a major impact on mRNA
degradation.7 By semiquantitative RT-PCR we were able
to show expression of EXPH5 mRNA in affected subject
and control skin, as well as obtaining RT-PCR amplification
from muscle, heart, and brain. We did not achieve ampli-
fication from kidney, liver, or lung (Figure S3).
To determine whether the loss-of-function mutation in
EXPH5 disrupts normal keratinocyte function, we first
examined the cytoskeletal architecture in keratinocytes
isolated from an affected individual as well as in normal1118 The American Journal of Human Genetics 91, 1115–1121, Dececontrol keratinocytes in which Slac2-b had been knocked
down by using retrovirally delivered shRNA (see Supple-
mental Data for methods). We noted disruption of the
keratin filament network and more cortically distributed
F-actin in both the patient and Slac2-b knockdown kerati-
nocytes compared to wild-type keratinocytes (Figure 3A).
The alteration in the keratin intermediate filaments, in
combination with the keratin filament aggregation seen
by transmission electron microscopy (Figures 1E–1G),
supports a role for Slac2-b in maintaining keratinocyte
integrity.
To determine whether Slac2-b-driven changes in cyto-
skeletal architecture led to altered cell function, we per-
formed keratinocyte adhesion assays to the extracellularmber 7, 2012
matrix protein, laminin-332. Data demonstrated signifi-
cantly reduced cell adhesion in both an affected person’s
cells (Figure 3B) and also the Slac2-b knockdown keratino-
cytes (Figure 3C) compared to respective controls. These
findings support a role for Slac2-b inmaintaining adhesion
between keratinocytes and basement membrane and
provide some insight into why skin fragility occurs in
affected family members. We also assessed localization of
Slac2-b and Rab27B in human keratinocytes by confocal
microscopy. Rab27B was mainly present in a perinuclear
distribution, whereas Slac2-b localized more to intracel-
lular vesicles and at the periphery of spreading cells where
some colocalization with Rab27B was seen (Figure 3D).
This finding suggests that Slac2-b and Rab27B colocalize
in certain cell compartments only during keratinocyte
adhesion and spreading. We also noted partial colocaliza-
tion of Slac2-b with b4 integrin at the periphery of
spreading cells (Figure 3D). Knockdown of Slac2-b led to
a dramatic reduction in levels of the b4 integrin subunit
at the plasma membrane as well as the cell surface glyco-
protein CD151 (Figure S2 and data not shown). Interest-
ingly, surface levels of b1 integrins were unchanged,
suggesting a specific role for Slac2-b in controlling b4
integrin function in keratinocytes (data not shown).
Rab proteins form part of the Ras superfamily of mono-
meric G proteins and more than 60 Rab proteins have
been identified in humans. Rab GTPases regulate many
key steps of cell membrane traffic, including vesicle forma-
tion, vesicle movement along actin and tubulin networks,
and membrane fusion (for review see Stenmark8). Rab
GTPases control trafficking in endocytic and secretory
pathways by recruiting proteins onto membrane surfaces
that can (1) drive cargo collection, (2) direct organelle
motility, or (3) steer vesicle docking at membranes. Many
Rab GTPases are differentially expressed in various tissues
and this diversity, in combination with differential expres-
sion of their numerous effector proteins (such as sorting
adaptors, tethering factors, kinases, phosphatases, motors,
etc.), accounts for a broad spectrum of biological func-
tions. Some inherited or acquired disorders of Rab path-
ways have been determined, the types of conditions
encompassing immunodeficiencies, infections, cancer,
and neurological disorders.9–13 With regard to inherited
skin diseases and GTPases, mutations in Rab27A and one
of its effector proteins, Slac2-a (also known as melanophi-
lin or exophilin-3), as well as Myosin Va, have been shown
to underlie the autosomal-recessive disorder Griscelli
syndrome (GS2 [MIM 607624]; GS3 [MIM 609227]; GS1
[MIM 214450], respectively)14–16 (Figure 2F). Similar
mutations in mice give rise to the ashen, leaden, and dilute
skin coat color abnormalities, respectively. In Griscelli
syndrome there is a pigmentary dilution in skin and
hair—this is the only phenotypic abnormality in GS3,
but in GS1 there are additional neurologic features and
in GS2 the syndrome includes neurologic and immuno-
logic defects.17 Rab27A recruits the adaptor protein Slac2-a
to the membranes of melanosomes and connects them toThe American Joumyosin Va.18 Slac2-a contains a N-terminal Slp-homology
domain (SHD) that binds to Rab27A, a central myosin-
binding domain, and a C-terminal actin-binding
domain.19 In contrast, the protein-protein interactions
for Slac2-b are less well defined: there is a Rab-binding
N-terminal SHD domain (amino acids 7–57) but no other
homology predicted binding sites apart from a possible
PDZ domain at the C terminus (within the part of the
protein truncated by the mutation in our pedigree).
Slac2-b lacks the C2A/C2B domains seen in other Rab27
effectors, domains that interact with SNARE fusion
machinery, and there is no sequence similarity with
domains interacting with motor linkers such as Myosin
Va, VIIa, and actin.19 Furthermore, in contrast to
Rab27A, Rab27B has a more restricted distribution, being
predominantly expressed in platelets, stomach, large intes-
tine, pancreas, pituitary, and bladder.20 Nevertheless,
a mouse model (lacking Rab27b but expressing lacZ under
the control of the Rab27b promoter) has shown that
Rab27b is also expressed in keratinocytes and indeed in
a few other cell types engaged in surface protection and
mechanical extension.20 Murine Rab27b/ knockouts
(and also double Rab27a/b knockouts) tend to have a
mild phenotype, although in one study, Rab27b knockout
led to a significant hemorrhagic disease with a reduction
in platelet granules and platelet serotonin content,
implying a role for Rab27B as a key regulator of dense
granule secretion.21 With regard to our pedigree pheno-
type, apart from occasional mild bruising, we did not
observe any clinical indicator of a significant platelet
anomaly. The major abnormality was skin fragility,
although the subtle diffuse pigmentary skin mottling
notedwas similar (but lessmarked) to the pigment changes
seen in Griscelli syndrome, a clinical observation that
could indicate some functional overlap/interplay for
Slac2-b with Rab27A, Slac2-a, and myosin-Va.
Further clues to the functions of Rab27A and Rab27B
have recently been gleaned from knockdown experiments
in HeLa cells.22 Notably, a small-scale shRNA screen identi-
fied Rab27A and its effector protein Slac2-a, as well as
Rab27B and its effector protein Slac2-b, as key drivers of
exosome vesicle release as well as the delivery of other
secretory vesicles. Exosomes are small membrane cup-
shaped vesicles, 40–100 nm in diameter, that are released
from many cell types when multivesicular endosomes
fuse with cell surfaces.23 Exosomes contain proteins
involved in lipid rafts, metabolism, adhesion, signaling,
T cell interactions, and cytoskeletal integrity.24 Knock-
down of Rab27A or Rab27B (or Slac2-a or Slac2-b) leads
to a decrease in the amount of exosomes secreted and
more motile multivesicular endosomes although the bio-
chemical composition of the exosomes is unchanged.22
The knockdown studies showed that Rab27A and Slac2-a
are needed for multivesicular endosome docking and
fusion, whereas Rab27B and Slac2-b probably link
microvesicular endosomes to outward directed motor
protein(s).22rnal of Human Genetics 91, 1115–1121, December 7, 2012 1119
The similarities in cell biologic abnormalities in both
the keratinocytes from an affected person and the Slac2-b
knockdown keratinocytes implies that the C-terminal
domain of Slac2-bmay be functionally significant, perhaps
with involvement in a key protein-protein interac-
tion germane to either generating the Slac-2b-Rab27B
complex and/or a direct domain interaction with a cyto-
skeletal or other protein; such data exist for Slac2-a but
not Slac2-b.25 Assessment of the Slac2-b sequence via
homology or ab initio protein structure prediction models
(including GlobProt, DisoPred, and ANCHOR), however,
fails to indicate a model structure or putative interacting
proteins. Studies on the C-terminal 100 amino acids of
Slac2-a have shown an interaction with the microtubule
end-binding EB1 protein25 but there are currently no
data to support similar biology for Slac2-b. Mutations in
Slac2-a, Rab27A, and Myosin Va all lead to perinuclear
accumulation of melanosomes in melanocytes. In con-
trast, mutations in Slac2-b result in accumulation of vesi-
cles close to nuclei in keratinocytes. Slac2-b mutations
also appear to disrupt the keratin filament cytoskeleton
(Figure 3A). Previously, a role for intermediate filaments
in organelle/adaptor protein positioning has been demon-
strated,26,27 and our new data support this interaction
but from the other perspective, namely that impairment
of the Slac2-b vesicle transport protein can lead to disrup-
tion of intermediate filaments. This vesicle trafficking/
intermediate filament disruption may also help explain
the ruffled or jagged appearance at the dermal-epidermal
junction on light microcopy and basement membrane
immunohistochemistry. Notably, normal transport of exo-
somes in cells involves physiologic transport and delivery
of morphogens and RNA, which can influence cell polarity
and developmental patterning of tissues,28 a process that
may be impaired in the presence of Slac2-b mutations.
In summary, we have used whole-exome sequencing to
identify a further cause of autosomal-recessive inherited
skin fragility. Our data expand the clinicopathological
spectrum of the epidermolysis bullosa group of diseases
and also demonstrate an unexpected role for Slac2-b in
keratinocyte cell biology.Supplemental Data
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